#1148 1987 · Merck & Co. (Roy Vagelos) · Pharmaceuticals / global health
Merck gave away its river-blindness cure free forever, to people who could never pay
the problem
Patients who need the cure cannot pay for it, so standard economics says shelve the drug
background
Merck researchers believed that ivermectin, a drug already used to treat parasites in livestock, could also cure human river blindness (onchocerciasis), a disease that was blinding hundreds of thousands of poor people across tropical Africa and Latin America. Proving it — development, human trials, mass manufacture and distribution — would take years and cost enormous sums, and every patient who needed the drug was too poor to pay anything for it.
The textbook business response was to leave the drug on the shelf: R&D poured into a medicine with zero paying market is money down the drain, and Merck already had a healthy market selling the same molecule to farmers. Any competent board would have asked why a profit-making company should spend a fortune to give medicine free to the poorest people on earth.
what everyone would do
Every textbook response fails: abandon the human indication to save R&D money (kills the value already found), keep the drug priced and watch nobody buy (there are no payers), or run a modest charity program on the side (fragile, seen as dabbling, no institutional commitment). None turns an orphan drug into an asset — they only cut losses or spend more.
what they saw
A product dies when sold to a market that cannot pay. Removing the price does not remove value — it moves drug to a ledger where effect compounds: reputation, institutional purpose, a gift unconditional cannot be undone.
the move
In 1987 Merck committed to donate Mectizan (ivermectin) completely free of charge, as much as needed and for as long as needed, to eliminate river blindness as a public health problem everywhere — then institutionalised the give-away by building the Mectizan Donation Program, a delivery partnership that shipped over 1.3 billion treatments in its first quarter-century.
why it works
When nobody can pay, price is not a lever — it is a wall, and zero is the only setting that lets the drug flow, so the give-away is what actually distributes value. Because the commitment is unconditional ('as much as needed, for as long as needed'), WHO, governments and distributors can build delivery infrastructure on a supply they can rely on, and that is what scales one molecule into over a billion doses. The unconditionality reads as trustworthy, so the company's reputational and institutional capital rises and becomes durable advantage — a firm that gave away a cure is later trusted to lead the disease's elimination, something a priced rival cannot touch. Zero price, reliable flow, coordinated infrastructure, institutional trust, durable value: each link feeds the next.
the payoff
Over 1.3 billion treatments donated; WHO verified five countries free of river blindness; 171 million people treated in 2024.
where it breaks
It fails when the give-away is not genuinely unconditional or when the recipient market cannot absorb it — a free drug means nothing without a delivery chain, which is why Merck had to build the partnership. It fails if other funders free-ride and the gift never becomes coordinated infrastructure. It fails where giving the product away cheapens a paying market that funds the research, or where the product is too dangerous or worthless to buy trust. And it requires the gift to outlast the need: a one-off donation is a write-off, not a strategy.
what came after
The Mectizan Donation Program became the institutional blueprint for corporate drug donation, copied by later large-scale giving for lymphatic filariasis and other neglected diseases, and the 1987 'free forever' commitment is now the standard mechanism for reaching markets that cannot pay.
references
- [1]Onchocerciasis — WHO fact sheetWorld Health Organization, 2026who.int
- [2]Growth, Challenges, and Solutions over 25 Years of Mectizan and the Onchocerciasis Control Program — PLOS NTDsPLOS Neglected Tropical Diseases, 2014journals.plos.org
- [3]Merck & Co., Inc.: Addressing Third-World Needs — HBS caseHarvard Business School, 1991hbsp.harvard.edu